cannabidiol addiction - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 3221

<< First< Prev

Page of 162

Next >Last >>

Select item 66805501.

Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms

Claudia Calpe-López, M. Pilar García-Pardo, Maria A. Aguilar

Molecules. 2019 Jul; 24(14): 2583. Published online 2019 Jul 16. doi: 10.3390/molecules24142583

PMCID:: PMC6680550

Article PubReader PDF–1.0M Cite

Select item 77953302.

Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals

Ewa Galaj, Zheng-Xiong Xi

Int J Mol Sci. 2021 Jan; 22(1): 134. Published online 2020 Dec 24. doi: 10.3390/ijms22010134

PMCID:: PMC7795330

Article PubReader PDF–790K Cite

Select item 91572443.

Cannabidiol and substance use disorder: dream or reality

Saeideh Karimi-Haghighi, Yasaman Razavi, Daniela Iezzi, Andrew F. Scheyer, Olivier Manzoni, Abbas Haghparast

Neuropharmacology. Author manuscript; available in PMC 2023 Apr 1.

Published in final edited form as: Neuropharmacology. 2022 Apr 1; 207: 108948. Published online 2022 Jan 13. doi: 10.1016/j.neuropharm.2022.108948

PMCID:: PMC9157244

Article PubReader PDF–528K Cite

Select item 46041784.

Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage

Yasmin L. Hurd, Michelle Yoon, Alex F. Manini, Stephanie Hernandez, Ruben Olmedo, Maria Ostman, Didier Jutras-Aswad

Neurotherapeutics. 2015 Oct; 12(4): 807–815. Published online 2015 Aug 13. doi: 10.1007/s13311-015-0373-7

PMCID:: PMC4604178

Article PubReader PDF–667K Cite

Select item 69102155.

CANNABIDIOL AS A NOVEL CANDIDATE ALCOHOL USE DISORDER PHARMACOTHERAPY: A SYSTEMATIC REVIEW

Jasmine Turna, Sabrina K. Syan, Benicio N. Frey, Brian Rush, Jean Costello, Mark Weiss, James MacKillop

Alcohol Clin Exp Res. Author manuscript; available in PMC 2020 Apr 1.

Published in final edited form as: Alcohol Clin Exp Res. 2019 Apr; 43(4): 550–563. Published online 2019 Feb 19. doi: 10.1111/acer.13964

PMCID:: PMC6910215

Article PubReader PDF–788K Cite

Select item 87995236.

A Scoping Review of the Use of Cannabidiol in Psychiatric Disorders

Anna E. Kirkland, Matthew C. Fadus, Staci A. Gruber, Kevin M. Gray, Timothy E. Wilens, Lindsay M. Squeglia

Psychiatry Res. Author manuscript; available in PMC 2023 Feb 1.

Published in final edited form as: Psychiatry Res. 2022 Feb; 308: 114347. Published online 2021 Dec 20. doi: 10.1016/j.psychres.2021.114347

PMCID:: PMC8799523

Article PubReader PDF–380K Cite

Select item 81730617.

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

Francisco Navarrete, María Salud García-Gutiérrez, Ani Gasparyan, Amaya Austrich-Olivares, Jorge Manzanares

Front Pharmacol. 2021; 12: 626010. Published online 2021 May 20. doi: 10.3389/fphar.2021.626010

PMCID:: PMC8173061

Article PubReader PDF–1.1M Cite

Select item 82986458.

Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review

Premalatha Balachandran, Mahmoud Elsohly, Kevin P. Hill

J Gen Intern Med. 2021 Jul; 36(7): 2074–2084. Published online 2021 Jan 29. doi: 10.1007/s11606-020-06504-8

PMCID:: PMC8298645

Article PubReader PDF–707K Cite

Select item 81248479.

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets

Rosa Maria Vitale, Fabio Arturo Iannotti, Pietro Amodeo

Int J Mol Sci. 2021 May; 22(9): 4876. Published online 2021 May 5. doi: 10.3390/ijms22094876

PMCID:: PMC8124847

Article PubReader PDF–2.7M Cite

Select item 845193410.

Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo‐controlled trial

Violaine Mongeau‐Pérusse, Suzanne Brissette, Julie Bruneau, Patricia Conrod, Simon Dubreucq, Guillaume Gazil, Emmanuel Stip, Didier Jutras‐Aswad

Addiction. 2021 Sep; 116(9): 2431–2442. Published online 2021 Feb 9. doi: 10.1111/add.15417

PMCID:: PMC8451934

Article PubReader PDF–793K Cite

Select item 609803311.

Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle

Gustavo Gonzalez-Cuevas, Remi Martin-Fardon, Tony M. Kerr, David G. Stouffer, Loren H. Parsons, Dana C. Hammell, Stan L. Banks, Audra L. Stinchcomb, Friedbert Weiss

Neuropsychopharmacology. 2018 Sep; 43(10): 2036–2045. Published online 2018 Mar 22. doi: 10.1038/s41386-018-0050-8

PMCID:: PMC6098033

Article PubReader PDF–1.2M Cite

Select item 470766712.

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J. Robson, Brian G. Rohrback, Elizabeth Thiele, Benjamin Whalley, Daniel Friedman

Epilepsia. Author manuscript; available in PMC 2016 Jan 11.

Published in final edited form as: Epilepsia. 2014 Jun; 55(6): 791–802. Published online 2014 May 22. doi: 10.1111/epi.12631

PMCID:: PMC4707667

Article PubReader PDF–361K Cite

Select item 581814713.

Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Natalie E. Zlebnik, Joseph F. Cheer

Annu Rev Neurosci. Author manuscript; available in PMC 2018 Feb 19.

Published in final edited form as: Annu Rev Neurosci. 2016 Jul 8; 39: 1–17. Published online 2016 Feb 24. doi: 10.1146/annurev-neuro-070815-014038

PMCID:: PMC5818147

Article PubReader PDF–358K Cite

Select item 769961314.

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

María S. García-Gutiérrez, Francisco Navarrete, Ani Gasparyan, Amaya Austrich-Olivares, Francisco Sala, Jorge Manzanares

Biomolecules. 2020 Nov; 10(11): 1575. Published online 2020 Nov 19. doi: 10.3390/biom10111575

PMCID:: PMC7699613

Article PubReader PDF–807K Cite

Select item 1019015015.

The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol

Alice Hartmann, Carla Vila-Verde, Francisco S. Guimarães, Sâmia R. Joca, Sabrina F. Lisboa

Curr Neuropharmacol. 2023 Feb 1; 21(2): 284–308. Published online 2023 Feb 1. doi: 10.2174/1570159X20666220411101217

PMCID:: PMC10190150

Article PubReader PDF–4.0M Cite

Select item 1004885716.

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure

Nicholas Pintori, Francesca Caria, Maria Antonietta De Luca, Cristina Miliano

Int J Mol Sci. 2023 Mar; 24(6): 5251. Published online 2023 Mar 9. doi: 10.3390/ijms24065251

PMCID:: PMC10048857

Article PubReader PDF–2.3M Cite

Select item 738542517.

Cannabidiol as a Treatment for Mood Disorders: A Systematic Review: Le cannabidiol comme traitement des troubles de l’humeur: une revue systématique

Jairo Vinícius Pinto, Gayatri Saraf, Christian Frysch, Daniel Vigo, Kamyar Keramatian, Trisha Chakrabarty, Raymond W. Lam, Márcia Kauer-Sant’Anna, Lakshmi N. Yatham

Can J Psychiatry. 2020 Apr; 65(4): 213–227. doi: 10.1177/0706743719895195

PMCID:: PMC7385425

Article PubReader PDF–410K Cite

Select item 689982218.

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

Gilmour Morrison, Julie Crockett, Graham Blakey, Kenneth Sommerville

Clin Pharmacol Drug Dev. 2019 Nov-Dec; 8(8): 1009–1031. Published online 2019 Feb 21. doi: 10.1002/cpdd.665

PMCID:: PMC6899822

Article PubReader PDF–2.6M Cite

Select item 559577119.

Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety‐related and substance abuse disorders

Jonathan L C Lee, Leandro J Bertoglio, Francisco S Guimarães, Carl W Stevenson

Br J Pharmacol. 2017 Oct; 174(19): 3242–3256. Published online 2017 Mar 9. doi: 10.1111/bph.13724

PMCID:: PMC5595771

Article PubReader PDF–386K Cite

Select item 727501820.

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

Elinor Ben-Menachem, Boudewijn Gunning, Carmen María Arenas Cabrera, Kevan VanLandingham, Julie Crockett, David Critchley, Louise Wray, Bola Tayo, Gilmour Morrison, Manuel Toledo

CNS Drugs. 2020; 34(6): 661–672. Published online 2020 Apr 30. doi: 10.1007/s40263-020-00726-4

PMCID:: PMC7275018

Article PubReader PDF–1008K Cite

<< First< Prev

Page of 162

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for cannabidiol addiction

Fig. 2

Staff attitudes toward the medical use of cannabidiol, by addiction experience (percentage responding either ‘agree’ or 'strongly agree’). Data labels represent percentages; differences are on chi-square testing; **p < 0.01

Staff awareness of the use of cannabidiol (CBD): a trust-wide survey study in the UK

J Cannabis Res. 2021;3:51.
Figure 1

Study inclusion process. CBD: Cannabidiol; THC: Δ9-Tetrahydrocannabinol.

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

J Clin Med. 2019 Jul;8(7):1058.
Fig. 4

Cannabidiol (CBD) effects on heroin self-administration and cue-induced heroin reinstatement behavior in rats showing CBD reduces heroin reinstatement behavior. Modified from Ren et al. []

Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage

Neurotherapeutics. 2015 Oct;12(4):807-815.
Fig. 2

Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) have opposing “yin/yang” effects on addiction-related behaviors. In contrast to THC that is rewarding and promotes drug use, CBD has low hedonic property and inhibits drug seeking

Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage

Neurotherapeutics. 2015 Oct;12(4):807-815.